Accueil   Diary - News   All news VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA® before 31 July 2019

VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA® before 31 July 2019

  • The results of this study will evaluate the efficacy of VALEDIA® in prediabetic subjects for the first time
  • Predicted to be the catalyst for concluding a commercial partnership with a major player in the healthcare sector
  • Beyond prediabetes, additional results are expected to shed light on the potential development of other applications of VALEDIA®

 

La Rochelle, 14 May 2019 (5:40 pm CEST) – VALBIOTIS FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the completion of the international Phase IIA clinical study evaluating VALEDIA® in prediabetic subjects, after the final follow-up visit was conducted with the last patient. VALBIOTIS will present the results of this study before 31 July 2019.

 

Read the press release

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service. More information... Close